Moderna receives u.s. fda approval for updated covid-19 vaccine

Clinical data show robust immune responses across multiple circulating variants, including eg.5, fl.1.5.1, and ba.2.86 updated vaccine to be available in pharmacies and care settings across the u.s. in the coming days cambridge, ma / accesswire / september 11, 2023 / moderna, inc. (nasdaq:mrna) today announced the u.s. food and drug administration (fda) has approved the supplemental biologics license application(sbla) for spikevax® for ages 12 years and above. emergency use authorization (eua) for the moderna covid-19 vaccine was also received for individuals 6 months through 11 years of age.
MRNA Ratings Summary
MRNA Quant Ranking